论文部分内容阅读
目的:评价胸腺肽α_1联合肝动脉化疗栓塞术治疗原发性肝癌的临床疗效和不良反应。方法:102例原发性肝癌患者随机分为2组,两组均接受肝动脉化疗栓塞术,治疗组在此基础上加用胸腺肽α_1皮下注射。观察两组不良反应发生情况,比较两组患者疗效及Karnofsky评分。结果:两组有效率差异无统计学意义(P>0.05),而肿瘤进展发生率与不良反应发生率比较,治疗组均低于对照组(P<0.05)。治疗后,治疗组Karnofsky评分高于对照组(P<0.05)。结论:胸腺肽α_1联合肝动脉化疗栓塞术治疗原发性肝癌安全、有效。
Objective: To evaluate the clinical efficacy and adverse reactions of thymosin α_1 combined with transcatheter arterial chemoembolization in the treatment of primary liver cancer. Methods: A total of 102 patients with primary liver cancer were randomly divided into 2 groups. Both groups received hepatic arterial chemoembolization. The treatment group was given subcutaneous injections of thymosin α_1. The incidence of adverse reactions in the two groups was observed. The curative effect and Karnofsky score were compared between the two groups. Results: There was no significant difference between the two groups (P> 0.05), but the incidence of tumor progression was significantly lower than that of the control group (P <0.05). After treatment, Karnofsky score in the treatment group was higher than that in the control group (P <0.05). Conclusion: Thymosin α_1 combined with transcatheter arterial chemoembolization in the treatment of primary liver cancer is safe and effective.